Faculty, Staff and Student Publications

Publication Date

3-1-2025

Journal

Gynecologic Oncology

DOI

10.1016/j.ygyno.2025.02.015

PMID

39987772

PMCID

PMC12115928

PubMedCentral® Posted Date

5-27-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Background: This study evaluated whether patients with epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) who are immediately re-treated with bevacizumab derive benefit after disease progression on a bevacizumab-containing regimen.

Methods: This multi-institutional, retrospective study compared patients with high grade non-mucinous epithelial OC who received bevacizumab followed directly by another bevacizumab-containing treatment regimen to patients who received bevacizumab followed by a regimen that did not contain bevacizumab (or received no further treatment). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan Meier product-limit estimator and modeled via Cox proportional hazards regression.

Results: Among 226 patients with OC who received bevacizumab as part of a treatment regimen,103 received sequential treatment with bevacizumab and 123 received a bevacizumab-containing regimen followed by a non-bevacizumab-containing regimen at the time of progression. Median follow-up for all subjects was 17.3 months (range, 1.2-138.2 months). Median PFS was 17.2 months (95 % CI, 14.3-21.2) for patients who received sequential bevacizumab re-treatment and 5.1 months (95 % CI, 4.3-6.3) for patients who received bevacizumab without bevacizumab-containing re-treatment (p < 0.001). Median OS was 29.9 months (95 % CI, 26.1-35.4) for patients who received sequential bevacizumab re-treatment (p < 0.001) and 12.4 months (95 % CI, 9.2-16.7) for patients who did not receive bevacizumab-containing re-treatment.

Conclusion: Patients with OC treated with bevacizumab-containing regimens sequentially at the time of progression have prolonged survival compared to patients who received no re-treatment with bevacizumab.

Keywords

Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carcinoma, Ovarian Epithelial, Disease Progression, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Progression-Free Survival, Retreatment, Retrospective Studies, ovarian cancer, fallopian tube cancer, bevacizumab, angiogenesis inhibitors

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.